M G Jones1, B G Marshall1, T J M Wallis2,3, E Heiden4, J Horno4, B Welham5, H Burke5, A Freeman5, L Dexter4, A Fazleen5, A Kong1, C McQuitty1, M Watson4, S Poole6, N J Brendish7, T W Clark6, T M A Wilkinson1. 1. Department of Respiratory Medicine and Southampton NIHR Biomedical Research Centre, University Hospital Southampton and School of Clinical and Experimental Sciences, Faculty of Medicine, University of Southampton, Southampton, UK. 2. Department of Respiratory Medicine and Southampton NIHR Biomedical Research Centre, University Hospital Southampton and School of Clinical and Experimental Sciences, Faculty of Medicine, University of Southampton, Southampton, UK. timothy.wallis@soton.ac.uk. 3. NIHR Southampton Biomedical Research Centre Research Fellow, University of Southampton, MP218 D-Level South Academic Block University Hospital Southampton, Southampton, SO16 6YD, UK. timothy.wallis@soton.ac.uk. 4. Department of Respiratory Medicine, University Hospital Southampton, Southampton, UK. 5. Department of Respiratory Medicine, University Hospital Southampton and School of Clinical and Experimental Sciences, Faculty of Medicine, University of Southampton, Southampton, UK. 6. Department of Infection and Southampton NIHR Biomedical Research Centre, University Hospital Southampton and School of Clinical and Experimental Sciences, Faculty of Medicine, University of Southampton, Southampton, UK. 7. Department of Infection, University Hospital Southampton and School of Clinical and Experimental Sciences, Faculty of Medicine, University of Southampton, Southampton, UK.
Abstract
BACKGROUND: The long-term consequences of COVID-19 remain unclear. There is concern a proportion of patients will progress to develop pulmonary fibrosis. We aimed to assess the temporal change in CXR infiltrates in a cohort of patients following hospitalisation for COVID-19. METHODS: We conducted a single-centre prospective cohort study of patients admitted to University Hospital Southampton with confirmed SARS-CoV2 infection between 20th March and 3rd June 2020. Patients were approached for standard-of-care follow-up 12-weeks after hospitalisation. Inpatient and follow-up CXRs were scored by the assessing clinician for extent of pulmonary infiltrates; 0-4 per lung (Nil = 0, < 25% = 1, 25-50% = 2, 51-75% = 3, > 75% = 4). RESULTS: 101 patients with paired CXRs were included. Demographics: 53% male with a median (IQR) age 53.0 (45-63) years and length of stay 9 (5-17.5) days. The median CXR follow-up interval was 82 (77-86) days with median baseline and follow-up CXR scores of 4.0 (3-5) and 0.0 (0-1) respectively. 32% of patients had persistent CXR abnormality at 12-weeks. In multivariate analysis length of stay (LOS), smoking-status and obesity were identified as independent risk factors for persistent CXR abnormality. Serum LDH was significantly higher at baseline and at follow-up in patients with CXR abnormalities compared to those with resolution. A 5-point composite risk score (1-point each; LOS ≥ 15 days, Level 2/3 admission, LDH > 750 U/L, obesity and smoking-status) strongly predicted risk of persistent radiograph abnormality (0.81). CONCLUSION: Persistent CXR abnormality 12-weeks post COVID-19 was common in this cohort. LOS, obesity, increased serum LDH, and smoking-status were risk factors for radiograph abnormality. These findings require further prospective validation.
BACKGROUND: The long-term consequences of COVID-19 remain unclear. There is concern a proportion of patients will progress to develop pulmonary fibrosis. We aimed to assess the temporal change in CXR infiltrates in a cohort of patients following hospitalisation for COVID-19. METHODS: We conducted a single-centre prospective cohort study of patients admitted to University Hospital Southampton with confirmed SARS-CoV2infection between 20th March and 3rd June 2020. Patients were approached for standard-of-care follow-up 12-weeks after hospitalisation. Inpatient and follow-up CXRs were scored by the assessing clinician for extent of pulmonary infiltrates; 0-4 per lung (Nil = 0, < 25% = 1, 25-50% = 2, 51-75% = 3, > 75% = 4). RESULTS: 101 patients with paired CXRs were included. Demographics: 53% male with a median (IQR) age 53.0 (45-63) years and length of stay 9 (5-17.5) days. The median CXR follow-up interval was 82 (77-86) days with median baseline and follow-up CXR scores of 4.0 (3-5) and 0.0 (0-1) respectively. 32% of patients had persistent CXR abnormality at 12-weeks. In multivariate analysis length of stay (LOS), smoking-status and obesity were identified as independent risk factors for persistent CXR abnormality. Serum LDH was significantly higher at baseline and at follow-up in patients with CXR abnormalities compared to those with resolution. A 5-point composite risk score (1-point each; LOS ≥ 15 days, Level 2/3 admission, LDH > 750 U/L, obesity and smoking-status) strongly predicted risk of persistent radiograph abnormality (0.81). CONCLUSION: Persistent CXR abnormality 12-weeks post COVID-19 was common in this cohort. LOS, obesity, increased serum LDH, and smoking-status were risk factors for radiograph abnormality. These findings require further prospective validation.
Authors: Nathan J Brendish; Stephen Poole; Vasanth V Naidu; Christopher T Mansbridge; Nicholas J Norton; Helen Wheeler; Laura Presland; Stephen Kidd; Nicholas J Cortes; Florina Borca; Hang Phan; Gavin Babbage; Benoit Visseaux; Sean Ewings; Tristan W Clark Journal: Lancet Respir Med Date: 2020-10-08 Impact factor: 30.700
Authors: Aditi S Shah; Alyson W Wong; James C Johnston; Christopher J Ryerson; Christopher Carlsten; Cameron J Hague; Darra T Murphy Journal: Thorax Date: 2020-12-03 Impact factor: 9.139
Authors: Swapna Mandal; Joseph Barnett; Simon E Brill; Jeremy S Brown; Emma K Denneny; Samanjit S Hare; Melissa Heightman; Toby E Hillman; Joseph Jacob; Hannah C Jarvis; Marc C I Lipman; Sindhu B Naidu; Arjun Nair; Joanna C Porter; Gillian S Tomlinson; John R Hurst Journal: Thorax Date: 2020-11-10 Impact factor: 9.139
Authors: Roberto Mogami; Ronaldo Carvalho Araújo Filho; Carolina Gianella Cobo Chantong; Fernando Carlos Santos de Almeida; Ana Célia Baptista Koifman; Gustavo Federico Jauregui; Thiago Thomaz Mafort; Hanna da Silva Bessa da Costa; Glenda Aparecida Peres Dos Santos; Bruna Zangerolame de Carvalho; Gabriel da Silva Passos; Erick de Souza Barbosa; Angelo Thomaz Abalada Ghetti; Laura Braga Monnerat; Mariana Soares da Cal; Desiree Louise Souza Santos Batista; Helen Aksenow Affonso; Gabriel Oliveira Bousquet; Jose Ignacio Marenco Avila; Anna Luiza Bento Dutra; Caio Leal Leidersnaider; Alexandre Malta da Costa Messeder; Alexandra Monteiro; Agnaldo José Lopes Journal: Radiol Res Pract Date: 2022-05-05
Authors: César Fernández-de-Las-Peñas; Juan Torres-Macho; Carlos M Elvira-Martínez; Luis J Molina-Trigueros; Tomas Sebastián-Viana; Valentín Hernández-Barrera Journal: Int J Clin Pract Date: 2021-09-29 Impact factor: 3.149